Preparation and characterization of biodegradable poly(l-lactide)/poly(ethylene glycol) microcapsules containing erythromycin by emulsion solvent evaporation technique

Erythromycin Formulations—A Journey to Advanced Drug Delivery

Erythromycin (ERY) is a macrolide compound with a broad antimicrobial spectrum which is currently being used to treat a large number of bacterial infections affecting the skin, respiratory tract, intestines, bones and other systems, proving great value from a clinical point of view. It became popular immediately after its discovery in 1952, due to its therapeutic effect against pathogens resistant to other drugs. Despite this major advantage, ERY exhibits several drawbacks, raising serious clinical challenges. Among them, the very low solubility in water and instability under acidic conditions cause a limited efficacy and bioavailability. Apart from this, higher doses promote drug resistance and undesirable effects. In order to overcome these disadvantages, during the past decades, a large variety of ERY formulations, including nanoparticles, have emerged. Despite the interest in ERY-(nano)formulations, a review on them is lacking. Therefore, this work was aimed at reviewing all efforts made to encapsulate ERY in formulations of various chemical compositions, sizes and morphologies. In addition, their preparation/synthesis, physico-chemical properties and performances were carefully analysed. Limitations of these studies, particularly the quantification of ERY, are discussed as well.

Preparation and characterization of long-term antibacterial and pH-responsive Polylactic acid/Octenyl succinic anhydride-chitosan @ tea tree oil microcapsules

Encapsulation technology can increase the stability and maintain the volatile active substances of plant essential oils. In the present study, tree essential oil (TTO) was encapsulated with polylactic acid (PLA) modified by octenyl succinic anhydride chitosan (OSA-CS) as shell materials to form long-term antibacterial and pH-responsive microcapsules. The PLA/OSA-CS@TTO microcapsules were characterized by high performance liquid chromatography (HPLC), scanning electron microscopy (SEM) and antibacterial performance testing. The results showed that the average particle size of microcapsules was 10 μm, and the encapsulation efficiency and drug loading efficiency of TTO reached 81.5 % and 60.3 %. After 4800 min of release in media at different pH (5 and 7) still sequestered 55.32 % and 56.74 % of TTO which approved the shell of microcapsules responded to different pH values. The microcapsules remained stable for 80 days after drying, and preserving 39.7 % of the core material. The morphology of PLA/OSA-CS@TTO microcapsules revealed that the PLA/OSA-CS@TTO microcapsules presented smooth and firm structure. Antibacterial test for staphylococcus aureus of those microcapsules implied that the bacteriostatic rate reached 100 % after 72 h. Bio-based macromolecular modification strategies can provide inspiration for the development of green microcapsules.

Preparation and Mechanical Properties of Microcapsule-Based Self-Healing Cementitious Composites

Self-healing concrete designs can protect against deterioration and improve durability. However, there is no unified conclusion regarding the effective preparation and mechanical properties of self-healing concrete. In this paper, microcapsules are used in cement-based materials, the reasonable dosage of microcapsules is determined, and the self-healing performance of the microcapsule self-healing system under different curing agents is explored. The microcapsules and curing agent are shown to enhance the flexural and compressive strength of mortar specimens at relatively low contents. The optimal microcapsule content in terms of compressive strength is 1–3%. When the content of the microcapsule reaches 7%, the strength of the specimen decreases by approximately 30%. Sodium fluorosilicate is better-suited to the microcapsule self-healing cement-based system than the other two fluorosilicates, potassium fluorosilicate and magnesium, which have similarly poor healing performance as curing agents. Healing time also appears to significantly influence the microcapsule self-healing system; mortar specimens that healed for 28 days are significantly higher than those that healed for 7 days. This work may provide a valuable reference for the design and preparation of self-healing cementitious composite structures.

Alginate hydrogel beads embedded with drug-bearing polycaprolactone microspheres for sustained release of paclobutrazol

In recent years there has been a growing demand for the development of agrochemical controlled release (CR) technologies. In the present study, we aimed to create a novel agricultural CR device using two polymeric systems that have been predominantly employed in biomedical applications: beads of alginate hydrogel embedded with drug-bearing Polycaprolactone (PCL) microspheres. The combined device utilizes the advantages of each polymer type for biodegradation and controlled release of Paclobutrazol (PBZ), a common growth retardant in plants. Surface morphology of the alginate beads was characterized by scanning electron microscopy (SEM) and water immersion tests were performed for stability and controlled release measurements. Bioassays were performed both in accelerated laboratory conditions and in field conditions. The results showed a capability to control the size of PBZ-loaded PCL microspheres through modification of homogenization speed and emulsifier concentration. Enlargement of PCL microsphere size had an adverse effect on release of PBZ from the alginate device. The growth of oatmeal plants as a model system was affected by the controlled release of PBZ. The preliminary field experiment observed growth retardation during two consecutive rainy seasons, with results indicating a substantial benefit of the sustained growth inhibition through the controlled release formulation. The final product has the potential to be used as a carrier for different substances in the agrochemical industry.

Fabrication and characterization of β-cypermethrin-loaded PLA microcapsules prepared by emulsion-solvent evaporation: loading and release properties

Microcapsulses can be designed to effectively encapsulate, protect, and control the release of pesticides. In this study, emulsion-solvent evaporation method was used to fabricate microcapsules using dichloromethane as the solvent, polylactic acid (PLA) as the carrier materials, poly(vinyl alcohol) as the emulsifier, and β-cypermethrin as the entrapped pesticide. The effects of process parameters on the microcapsules characteristics (size, loading content, and encapsulation efficiency) were investigated. Also, the release behavior of the β-cypermethrin was measured experimentally and modeled mathematically. Kinetic analysis indicated that release mechanism of β-cypermethrin was compatible to Fickian diffusion. By optimizing the process parameters, β-cypermethrin-loaded microcapsules were successfully produced with spherical shape, smooth surface, high encapsulation efficiency (> 80%), and a range of pesticide contents. These parameters could be adjusted to achieve delivery systems with desirable release profiles. The results are beneficial to develop delivery systems for rational and effective usage of pesticides.

Investigation of a New Microcapsule Membrane Combining Alginate, Chitosan, Polyethylene Glycol and Poly-L-Lysine for Cell Transplantation Applications

Microencapsulation of living cells may serve as an alternative therapy for patients requiring organ transplants. One of the limiting factors in the progress of such therapy is attaining a biocompatible and mechanically stable polymer. The current study investigates the potential of a novel membrane combining alginate, chitosan, polyethylene glycol (PEG) and poly-L-lysine (PLL) with the objective of proposing a membrane suitable for cell entrapment that may overcome some of the shortcomings of the widely studied alginate-poly-L-lysine-alginate (APA) capsules. The novel microcapsule was formulated using a 1.5% alginate solution coated with 0.05% chitosan, 0.1% PEG and 0.05% poly-L-lysine with a final layer of 0.1% alginate. Microcapsules having a diameter of 450 ± 30 μm were prepared. Upon citrate treatment, the membrane remained intact and retained its spherical structure. The membrane was able to support liver cell proliferation and the encapsulated cells were capable of secreting proteins. The study demonstrated that the new membrane can be used for cell entrapment. However, further investigations are needed to assess its potential for long term transplantation and usage in the development of bioartificial organs.

Design of experiments for microencapsulation applications: A review

Microencapsulation techniques have been intensively explored by many research sectors such as pharmaceutical and food industries. Microencapsulation allows to protect the active ingredient from the external environment, mask undesired flavours, a possible controlled release of compounds among others. The purpose of this review is to provide a background of design of experiments in microencapsulation research context. Optimization processes are required for an accurate research in these fields and therefore, the right implementation of micro-sized techniques at industrial scale. This article critically reviews the use of the response surface methodologies in pharmaceutical and food microencapsulation research areas. A survey of optimization procedures in the literature, in the last few years is also presented.

End-chain fluorination of polyesters favors perfluorooctyl bromide encapsulation into echogenic PEGylated nanocapsules

Fluorination of polyesters favors the encapsulation efficiency of perfluorooctyl bromide into nanocapsules.

Controlled pesticide release from biodegradable polymers

Polymers have been widely used in agriculture for applications including controlled release of pesticides and other active ingredients. The ability to predict their delivery helps avoid environmental hazards. Macromolecular matrices used as carriers in controlled release of agricultural active agents, especially pesticides, are reviewed. The review focuses on the advantages and mechanisms of controlled release. It includes biodegradable polymers in agriculture, their manufacturing methods, and their degradation mechanisms and kinetics. The article also presents a critical account of recent release studies and considers upcoming challenges.

Preparation, characterization and in vitro release properties of morphine-loaded PLLA-PEG-PLLA microparticles via solution enhanced dispersion by supercritical fluids

Morphine-loaded poly(L-lactide)-poly(ethylene glycol)-poly(L-lactide) (PLLA-PEG-PLLA) microparticles were prepared using solution enhanced dispersion by supercritical CO2 (SEDS). The effects of process variables on the morphology, particles size, drug loading (DL), encapsulation efficiency and release properties of the microparticles were investigated. All particles showed spherical or ellipsoidal shape with the mean diameter of 2.04-5.73 μm. The highest DL of 17.92 % was obtained when the dosage ratio of morphine to PLLA-PEG-PLLA reached 1:5, and the encapsulation efficiency can be as high as 87.31 % under appropriate conditions. Morphine-loaded PLLA-PEG-PLLA microparticles displayed short-term release with burst release followed by sustained release within days or long-term release lasted for weeks. The degradation test of the particles showed that the degradation rate of PLLA-PEG-PLLA microparticles was faster than that of PLLA microparticles. The results collectively suggest that PLLA-PEG-PLLA can be a promising candidate polymer for the controlled release system.

Biphasic release of protein from polyethylene glycol and polyethylene glycol/modified dextran microspheres

Dextrans show great promise for delivery of therapeutic agents. Dextran acetates (DAs) were synthesized with increasing degrees of substitution (DA1 < DA2 < DA3) by the reaction of the polysaccharide dextran (70 kDa) with acetic anhydride. A series of polyethylene glycol (PEG)/DA microspheres were prepared and tested with bovine serum albumin (BSA) functioning as a model protein. Particle size (0.74-0.85 μm) and encapsulation efficiency (56-70%) increased with the degree of substitution along with a slower release rate of protein from PEG/DA microspheres. Time to release 90% of protein rose from 31 to 118 min. Percentage of BSA released from PEG and PEG/DA3 microspheres with time (min) was modeled mathematically [Y(PEG) = 100(1 - e(-0.12t)); Y(PEG/DA3) = 100(1 - e(-0.024t))] to predict cumulative delivery from mixtures in vitro over a period of hours when constrained to a target level at 30 min. The system is examined for potential application in thrombolytic therapy.

Porosity and semipermeability of hemoglobin-loaded polymeric nanoparticles as potential blood substitutes

Porosity and semipermeability, allowing life-sustaining small molecules to penetrate, but hemoglobin (Hb) and other enzymes to cut off, predominantly affect the functionalities of the Hb-loaded polymeric nanoparticles (HbPNPs) as blood substitutes. In this article, HbPNPs formulated in the size range of 110-122 nm were prepared by a modified double-emulsion method with poly(lactic acid) (PLA)-based polymers. The influences of the main preparation conditions, including solvent composition, stirring speed, Hb concentration and polymer matrix, on the porosity were investigated in details. To evaluate the porosity of HbPNPs, a novel nondestructive testing method based on molecular weight cut-off (MWCO) was developed, and an effusion approach was applied to investigate the pore size in the particle shells with poly(ethylene glycol)s (PEGs) of different molecular weights (PEG200, PEG400, PEG600) as probes. Moreover, in vitro diffusion behaviors of ascorbic acid and reduced glutathione from HbPNPs fabricated with various polymer matrices were studied. The MWCO of HbPNPs by changing solvent composition, stirring speed, Hb concentration, and polymer composition varied from 200 to 600, especially the PEGylation of the polymer, which exhibited obvious influence on the MWCO of HbPNPs. Ascorbic acid with molecular weight 176.1 could diffuse into PEGylated nanoparticles with mPEG content of 5-30 wt % freely, while reduced glutathione with molecular weight 307.3 could not penetrate when mPEG content reached 30 wt %. These results suggest that the HbPNPs optimized with MWCO between 400 and 600 can facilitate the transport of all those life-sustaining small molecules.

Effect of molecular weight, crystallinity, and hydrophobicity on the acoustic activation of polymer-shelled ultrasound contrast agents

Polymer-shelled microbubbles are applied as ultrasound contrast agents. To investigate the effect of the polymer on microbubble preparation and acoustic properties, polylactides with systematic variations in molecular weight, crystallinity, and end-group hydrophobicity were used. Polymer-shelled cyclodecane filled capsules were prepared by emulsification, and the cyclodecane was removed by lyophilization to obtain hollow capsules. Complete removal of cyclodecane from the microcapsules was only achieved for short chain (about M(w) 6000) crystalline polymers. The pressure threshold for acoustic destruction of the microbubbles was found to increase with molecular weight. Noncrystalline polymers showed a higher threshold for destruction than crystalline polymers. Hydrophobically modified short chain crystalline polymers showed the steepest increase in acoustic destruction after the threshold as a function of the applied pressure, which is a favorable characteristic for ultrasound mediated drug delivery. Microcapsules made with such polymers had an inhomogeneous surface including pores through which cyclodecane was lyophilized efficiently.

Coating of indomethacin-loaded embolic microspheres for a successful embolization therapy

Indomethacin-loaded dietheylaminoethyl trisacryl microspheres (DEAE-MS), originally designed for therapeutic embolization, were encapsulated using two methods: coacervation and solvent evaporation/extraction. This encapsulation was achieved using a biocompatible polymer, the PLGA 50 : 50, and aimed to control the release of the anti-inflammatory non-steroidal drug (AINSD) in the occluded vessel. PLGA degradation study showed that it had an erosion half-life of approximately 35 days. Scanning electron microscopy (SEM) photographs showed that microcapsules (MC) prepared by coacervation had a wrinkled surface while those prepared using solvent-removal process showed non-porous, smooth surface, those of originally DEAE-MS showed a macro-porous, rough surface. The mean diameters were 61 microm for naked DEAE-MS vs. 71 microm and 65 microm for MC prepared by coacervation and solvent evaporation/extraction method, respectively. In vitro release study of indomethacin adsorbed onto MS indicated that drug release from MC was controlled by a diffusion process. Indomethacin diffusivity from MC was much lower than its free diffusivity from MS (mean 14.5 and 10.5 times lower for formulations prepared by coacervation and solvent evaporation/extraction method, respectively). This indicates that efficient indomethacin concentrations could be maintained over much longer time-periods in the embolized region, which is assumed to be beneficial in inhibiting normally occurring inflammatory reaction and the subsequent revascularization; responsible for treatment failure when definitive occlusion is required.

Controlling protein release from scaffolds using polymer blends and composites

We report the development of three protein loaded polymer blend and composite materials that modify the release kinetics of the protein from poly(dl-lactic acid) (P(dl)LA) scaffolds. P(dl)LA has been combined with either poly(ethylene glycol) (PEG), poly(caprolactone) (PCL) microparticles or calcium alginate fibres using supercritical CO(2) (scCO(2)) processing to form single and dual protein release scaffolds. P(dl)LA was blended with the hydrophilic polymer PEG using scCO(2) to increase the water uptake of the resultant scaffold and modify the release kinetics of an encapsulated protein. This was demonstrated by the more rapid release of the protein when compared to the release rate from P(dl)LA only scaffolds. For the P(dl)LA/alginate scaffolds, the protein loaded alginate fibres were processed into porous protein loaded P(dl)LA scaffolds using scCO(2) to produce dual release kinetics from the scaffolds. Protein release from the hydrophilic alginate fibres was more rapid in the initial stages, complementing the slower release from the slower degrading P(dl)LA scaffolds. In contrast, when protein loaded PCL particles were loaded into P(dl)LA scaffolds, the rate of protein release was retarded from the slow degrading PCL phase.

PEGylation of microspheres for therapeutic embolization: Preparation, characterization and biological performance evaluation

In this study, microspheres designed for embolization, defined as GF2000-Trisacryl MS (GF-MS) and DEAE-Trisacryl MS (DEAE-MS), were originally PEGylated using (3-amino propyl) triethoxy silane as coupling agent. Indomethacin was loaded into both PEGylated and non-PEGylated DEAE-MS, displaying ion-exchange ability, through a batch process with a respective capacity of 1.2 and 0.25 g/g. The morphology of naked and PEGylated MS was evaluated by scanning electron microscopy (SEM). Both micosphere resins surface looked like orange skin, although DEAE-MS showed a slightly rougher surface due to the copolymerization process. PEGylated microspheres have a most likely swelling surface owing to the presence of PEG hydrophilic chains. The mean diameters were of about 66 and 60 microm for GF-MS and DEAE-MS, respectively. Data obtained for PEGylated MS by Fourier Transform Infrared spectroscopy (FTIR) confirmed that microspheres were successfully PEGylated. Finally, complement activation in vitro was performed to evaluate the activating capacity of different microspheres. Both PEGylated GF-MS and DEAE-MS activated the complement system of about 33% less than their corresponding naked microspheres, while loading PEGylated DEAE-MS with indomethacin almost suppressed complement activation. This inhibiting role implies that PEGylation as well as loading the microspheres with anti-inflammatory drug has a compact effect on the interaction of microspheres with blood proteins.

Synthesis and characterization of PLGA nanoparticles

Poly(lactide-co-glycolide) (PLGA) nanoparticles of different physical characteristics (size, size distribution, morphology, zeta potential) can be synthesized by controlling the parameters specific to the synthesis method employed. The aim of this review is to clearly, quantitatively and comprehensively describe the top-down synthesis techniques available for PLGA nanoparticle formation, as well as the techniques commonly used for nanoparticle characterization. Many examples are discussed in detail to provide the reader with an extensive knowledge base on the important parameters specific to the synthesis method described and ways in which these parameters can be manipulated to control the nanoparticle physical characteristics.

Small-molecule release from poly(D,L-lactide)/poly(D,L-lactide-co-glycolide) composite microparticles

Addition of biodegradable polymer shells surrounding polymeric, drug-loaded microparticles offers the opportunity to control drug release rates. A novel fabrication method was used to produce microparticles with precise control of particle diameter and the thickness of the polymer shell. The effect of shell thickness on release of a model drug, piroxicam, has been clearly shown for 2- to 15-microm thick shells of poly(D,L-lactide) (PDLL) surrounding a poly(D,L-lactide-co-glycolide) (PLG) core and compared to pure PLG microspheres loaded with piroxicam. Furthermore, the core-shell microparticles are compared to microspheres containing blended polymers in the same mass ratios to demonstrate the importance of the core-shell morphology. Combining PDLL(PLG) microcapsules of different shell thicknesses allows nearly constant release rates to be attained for a period of 6 weeks.